Drug Profile
Research programme: matrix metalloproteinase inhibitors - British Biotech/Schering-Plough
Latest Information Update: 30 May 2007
Price :
$50
*
At a glance
- Originator British Biotech; Schering-Plough
- Class
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 02 Apr 2003 No development reported - Preclinical for Solid tumours in United Kingdom (unspecified route)
- 14 Aug 2001 Preclinical development for Solid tumours in United Kingdom (Unknown route)